"description","uuid:ID","label","id","name","text","instanceType"
"Main objective","6a6b4bf5-f14c-4c69-81f6-4e38877faf0e","","Objective_1","OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","OBJECTIVE"
"Safety","b68fda36-91e0-44ca-8fd6-844804e5bdad","","Objective_2","OBJ2","To document the safety profile of the xanomeline TTS.","OBJECTIVE"
"Behaviour","004be5bc-19ee-46c9-a54e-716308cd35cd","","Objective_3","OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","OBJECTIVE"
